key: cord-0713937-hrtv4euo
authors: Salciccioli, Justin D.; She, Lilin; Tulchinsky, Abigail; Rockhold, Frank; Cardet, Juan Carlos; Israel, Elliot
title: Effect of Covid19 on asthma exacerbation
date: 2021-04-30
journal: J Allergy Clin Immunol Pract
DOI: 10.1016/j.jaip.2021.04.038
sha: 0b0bf1df3e22d56a2558c8ce59c87d19ed259fc4
doc_id: 713937
cord_uid: hrtv4euo

nan

Outcomes Research Institute (PCORI) Project Program Award (PCS-1504-30283) . There were 29 no additional funds for this work. All statements in this work represent the work of the authors 30 and do not represent the views of PCORI, the Board of Governors or Methodology Committee. 31 32 J o u r n a l P r e -p r o o f

For Black/African-American and Hispanic/Latinx individuals with moderately severe asthma, 34 there was nearly a halving of asthma exacerbations following the COVID19 pandemic, a 35 decrease most significant for individuals working outside of the home and in those without type 36 2 inflammation suggesting environmental or common viral triggers for asthma exacerbations. 37 J o u r n a l P r e -p r o o f

Understanding the effect of the COVID-19 pandemic, and the efforts taken to combat it, 39 on specific diseases is difficult due to the many ways in which COVID-19 is impacting patients 40 and healthcare systems. A significant decrease in the utilization of emergency services for 41 asthma exacerbation (AEX) has been reported (1). However, healthcare system avoidance has 42 also been reported, and has resulted in delayed or decreased primary and acute care 43 consultations making it difficult to assess extent to which decreased health utilization is related 44 to patient avoidance of health services versus actual changes in asthma control (2). 45

The PREPARE Study is a national randomized, open-label, pragmatic trial of a patient-46 guided, reliever-triggered inhaled corticosteroid strategy in African-American/Black (AA/B) and 47

Hispanic/Latinx (H/L) adults (age 18-75) with moderate-to-severe asthma (3). Subject 48 recruitment occurred at 19 clinical organizations across the US, including 4 primary care and 6 49 specialty practices, and 9 combined primary and specialty care practices (Table E1) . Following 50 a single in-person appointment at enrollment, participants completed monthly questionnaires 51 remotely either online, by phone, or by mail for 15 months. The study's primary outcome was 52 annualized asthma exacerbation rate and exacerbations as defined by Wechsler et al (4) self-53 reported via a monthly Asthma Exacerbation Questionnaire (AEQ), verified and adjudicated 54 remotely. Recruitment into the trial was initiated in November 2018 and enrollments were 55 completed in March 2020, as COVID19-related lockdowns were initiated. Since remote 56 reporting of asthma control is unlikely to be affected by healthcare-system avoidance, these 57 data provide a unique opportunity to understand changes in asthma control during the COVID-58 19 pandemic. 59

We compared the change in annualized asthma exacerbation rates between the first and 60 second quarters of 2019 versus 2020. The outcome was categorized by month and by quarter 61 of the observation year [first quarter (Q1): 1st January through 31st March; second quarter correlation structure were used, with exacerbation count as a function of quarter (Q1 compared 65 to Q2) for both 2019 and 2020, with repeated measurement on subjects across calendar 66 quarters. The influence of relevant covariates on outcomes was assessed using multivariable 67 regression and testing for the independent interaction between covariate and outcomes. 68

Potential covariates were selected a priori on the basis of potential clinical relevance and 69 included race, hypertension, geographic region, and place of work at enrollment (at home or 70 working outside of the home). The effect of obesity and eosinophilic phenotypes (peripheral 71 blood eosinophilia and fractional excretion of nitric oxide (FeNO) data, where available) were 72 also examined. The DID effect was also examined after adjusting for the air quality factors. 73

A total of 1178 participants were included and baseline characteristics are shown in 74 Table E2 . There were more H/L participants and more participants from the Southwest in 2020 75 and no other clinically significant differences in baseline characteristics between 2019 and 2020. 76

At entry, 55% were not working outside of the home and 72% had an asthma exacerbation in 77 the year prior to enrollment. There were a total of 682 AEX events, of which 334 (49%) occurred 78 in the context of in-person healthcare contact. AEX rates in the first and second quarters of 79 2019 and 2020 are shown in Figure 1 . There was a significant decrease from Q1 to Q2 of 2020 80 when compared to the same time period in 2019, with a DID of -0.47 exacerbations per year 81 (95% CI -0.76, -0.19; p = 0.001) and which represents a relative reduction of 41% (Table 1) . 82 AEX decreased 50% in H/L and 27% in AA/B (DID -0.64, 95% CI -1.05, -0.24 (p = 0.002) and -83 0.28, 95% CI -0.75, 0.18 (p = 0.2), respectively). Participants who worked outside of the home 84 at study entry had a 65% decrease (DID -0.73, 95% CI -1.12, -0.34; p < 0.001) compared to 85 those who worked at home with a 23% decrease (DID -0.27, 95% CI -0.69, 0.15; p = 0.2). AEX 86 decreases were greater for individuals without a type-2 helper T-cell phenotype. Specifically, 87 (Table 1) . Decreased exacerbations remained significant after controlling for changes in PM2.5 91 (p = 0.005), NO2 (p = 0.017) and ozone (p = 0.0028). There were no statistically significant 92 interactions between the AEX outcome and the pre-specified covariates of by race, obesity, 93 hypertension, geographic region, and place of work. 94

In this multicenter study of AA/B and H/L adults with asthma, there was a significant 95 reduction in AEX rates with the COVID-19 pandemic. The effect was greatest in H/L individuals, 96 those working outside the home at the time of enrollment, and in those with non-type-2 97 inflammation (ie. low blood eosinophil count and low FeNO). Puerto Rico, the site of enrollment 98 of most H/L subjects, showed the greatest reduction in exacerbations. Similarly, non-99 hypertensive patients (more likely to be H/L) also had a greater reduction. 100

This is the first study to assess AEX before and after the COVID-19 pandemic using 101 data that are unlikely to be affected by healthcare system avoidance. Previous studies have 102 reported reduced hospital and emergency presentations for asthma and were unable to 103 differentiate changes in health-seeking behavior versus true reductions in in the occurrence of 104 episodes of asthma. Thus, it is possible that the prior reports of reduced exacerbations reflect 105 this reluctance to initiate face-to-face provider contact. Since the present data include 106 exacerbations that did not necessarily require healthcare facility interaction and are entirely 107 reported remotely, they suggest a true reduction in the totality of asthma exacerbation following 108 the pandemic. Importantly, the magnitude of this reduction is substantial, with an effect similar to 109 that seen with biologic therapies for severe asthma (5,6). 110

Potential explanations for the observed decreases in AEX may include decreased 111 exposure to environmental and occupational factors, reduced respiratory infections , and/or 112 changes in stress. Previous reports have highlighted that allergen exposure and viral pathogens home on entry to the study and may relate to reduced environmental exposures or viral 116 exposure through person-to-person contact that may be greater in those working outside the 117 home which may have been reduced by subsequent relocation of the work environment. 118

However, it is unlikely that changes in workplace location alone accounts for the dramatic 119 reduction as occupational exposures account for between 9 and 15% of asthma cases (8, 9) . 120

The additional finding of greater reduction in individuals with low type-2 inflammation, suggested 121 that viral and/or occupational precipitants may be more important contributors to exacerbation in 122 those individuals compared to individuals with intrinsic type-2 inflammation. 123

Since we only studied AA/B and H/L patients, it is possible that our results do not 124 generalize to the entire population. Although the magnitude of effect might be different in other 125 racial or ethnic groups, much of the basic biology of asthma is common to all populations. While 126 half of our population received usual asthma care plus as needed ICS, we do not believe that 127 this significantly alters the impact of our findings since international guidelines recommend 128 some form of as needed ICS in addition to usual care for patients enrolled in our study. 129

Workplace location details were collected at baseline and therefore it is possible that 130 employment change as a result of the pandemic may have also influenced the observed 131 decreases. 132

In summary, we show that total asthma exacerbations decreased by greater than 40% 133 coincident with the onset of the COVID-19 pandemic. Reductions in exacerbation were greatest 134 in individuals who were working outside of the home and in those without type 2 inflammation. 135

This effect may be related to social-distancing and occupational changes and unlikely to be 136 related to reduced health-system avoidance during the COVID-19 pandemic. Given the 137 significant morbidity associated with AEX, further investigation is required to further clarify the 138 underlying causes of these findings. 139 J o u r n a l P r e -p r o o f 

Age (yrs), mean (SD)

AEX: asthma exacerbation; ACT: Asthma Control Test; ASUI: Asthma Symptom Utility Index; BMI: body mass index; COPD: Chronic Obstructive Pulmonary Disease

J o u r n a l P r e -p r o o f